Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinderella-Neo: Triple-targeted Anti-HER2 and CDK4/6 Inhibitors in Neoadjuvant ER+/HER2+ Breast Cancer
NCT07290166Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of pyrotinib, trastuzumab, pertuzumab in breast cancer, sponsored by Fudan University. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07290166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290166.